A 10-Year, Post-marketing, Observational, Registry to Assess Long Term Safety of HUMIRA (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (Ps)

Trial Profile

A 10-Year, Post-marketing, Observational, Registry to Assess Long Term Safety of HUMIRA (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (Ps)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Acronyms ESPRIT
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 26 Sep 2016 Interim results will be presented at the 25th European Academy of Dermatology and Venereology Congress (EADV), as per AbbVie media release.
    • 08 Mar 2016 Six year interim results presented at the 74th Annual Meeting of the American Academy of Dermatology
    • 02 Mar 2016 Six year interim results will be presented at the upcoming 74th Annual Meeting of the American Academy of Dermatology (AAD), as per AbbVie media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top